sucroferric oxyhydroxide

This medicine is authorised for use in the European Union.


Velphoro is a medicine used to control blood-phosphate levels in patients with long-term kidney disease:

  • in adults who are on haemodialysis or peritoneal dialysis to remove waste products from the blood;
  • in children aged from 2 years with severe kidney disease, including those on dialysis.

Velphoro should be used with a low-phosphate diet and other treatments such as calcium and vitamin D supplements which help to control bone disease linked to kidney failure and high phosphate levels.

The active substance in this medicine is sucroferric oxyhydroxide (also known as mixture of polynuclear iron(III)-oxyhydroxide, sucrose (sugar) and starches).

This EPAR was last updated on 03/02/2021

Authorisation details

Product details
Agency product number
Active substance
Sucroferric oxyhydroxide
International non-proprietary name (INN) or common name
sucroferric oxyhydroxide
Therapeutic area (MeSH)
  • Hyperphosphatemia
  • Renal Dialysis
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Vifor Fresenius Medical Care Renal Pharma France
Date of issue of marketing authorisation valid throughout the European Union
Contact address
100-101 Terrasse Boieldieu
Tour Franklin- La Défense 8
92042 Paris la Défense Cedex

Product information

16/11/2020 Velphoro - EMEA/H/C/002705 - X/0020/G


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Drugs for treatment of hyperkalemia and hyperphosphatemia

Therapeutic indication

Velphoro is indicated for the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD).

Velphoro is indicated for the control of serum phosphorus levels in paediatric patients 2 years of age and older with CKD stages 4-5 (defined by a glomerular filtration rate <30 mL/min/1.73 m²) or with CKD on dialysis.

Velphoro should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin D3 or one of its analogues, or calcimimetics to control the development of renal bone disease.

Assessment history

Related content

How useful was this page?

Add your rating